文献速递乳腺乳腺X线US

对初次影像引导穿刺活检诊断为恶性潜能不确定(B3)乳腺筛查病灶的审计:10 年来我们的实践发生了哪些变化

An audit of mammographic screen detected lesions of uncertain malignant potential (B3) diagnosed on initial image guided needle biopsy: how has our practice changed over 10 years?
PubMed 文献 · Clin Radiol · 2019-05-09

回顾性审计两个 5 年队列中初次影像引导穿刺活检诊断的 B3 病灶,2005-2010 年 224 例、2010-2015 年 240 例,乳腺 X 线特征无差异;后一队列良性手术活检减少、二线真空活检/切除增加,升级率无显著变化;总体 6% 升级为浸润性癌、13% 升级为导管原位癌。

要点

  • B3 病灶总体 6% 升级为浸润性癌、13% 升级为导管原位癌。
  • 伴不典型增生的乳头状瘤升级率 53.8%(7/13),不伴不典型增生者 12.1%(8/66)。
  • 后一队列良性手术活检减少、二线真空活检/切除增加,升级率无显著变化。

核心结论

  • 即使一线使用真空活检,部分组织学类别的升级率仍较高;交界性病灶的处理应在多学科会议上审慎考虑;许多情况下诊断性手术切除的需求已被影像引导真空取样替代。

研究设计与样本

  • 回顾性数据收集,两个 5 年队列(2005-2010 年 224 例,2010-2015 年 240 例),记录每个病灶的乳腺 X 线特征、活检类型和处理,量化各 B3 组织学类别的升级率,使用 SPSS 进行统计分析。

关键影像表现/征象

  • 乳腺 X 线上 211 个病灶为微钙化、182 个为肿块、65 个为结构扭曲、6 个为非对称致密,两个队列的乳腺 X 线特征无差异。

诊断标准与关键数值

  • 总体升级为浸润性癌 6%,升级为导管原位癌 13%。
  • 不典型导管内上皮增生(AIDEP)升级率 33.2%(21/63)。
  • 经典型(非多形性)原位小叶肿瘤(ISLN)升级率 18.2%(6/33)。
  • 扁平上皮增生(FEA)升级率 21.7%(20/92)。
  • 伴不典型增生的乳头状瘤升级率 53.8%(7/13),不伴不典型增生者 12.1%(8/66);伴不典型增生的放射状瘢痕/复杂硬化性病变升级率 16.7%(2/12),不伴不典型增生者 7.9%(6/76)。

临床应用与阅片要点

  • 作者认为交界性病灶的处理应在多学科会议上审慎考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To review all cases of B3 lesion diagnosed at initial image-guided needle biopsy over two 5-year cohorts to identify upgrade rates to malignancy and the effect of changing guidance on the management of such lesions.

MATERIALS AND METHODS: Data was collected retrospectively. Mammographic features, biopsy type and management were recorded for each lesion. Upgrade rates for each B3 histological category were quantified. Statistical analysis was performed using SPSS.

RESULTS: There were 224 cases in 2005-2010 and 240 cases in 2010-2015. Mammographically 211 lesions were microcalcifications, 182 masses, 65 distortions and six asymmetric densities with no difference in the mammographic features in the two cohorts. Two hundred and eight 14 G core biopsies and 256 initial vacuum-assisted biopsies were performed. There was a statistically significant reduction in benign surgical biopsies and an increase in second-line vacuum biopsy/excision in the latter cohort, with no significant change in the upgrade rate. There was an overall 6% upgrade to invasive malignancy and 13% upgrade to ductal carcinoma in situ (DCIS). The upgrade rates for the following histological categories were atypical intraductal epithelial proliferation (AIDEP) 33.2% (21/63); classical (not pleomorphic) in situ lobular neoplasia (ISLN) 18.2% (6/33); flat epithelial hyperplasia (FEA) 21.7% (20/92); papilloma with atypia 53.8% (7/13), without atypia 12.1% (8/66); and radial scar/complex sclerosing lesion with atypia 16.7% (2/12), and without atypia 7.9% (6/76).

CONCLUSION: Upgrade rates remain high for some histological categories even with first-line use of vacuum biopsy. Management of borderline lesions should be considered carefully in a multidisciplinary meeting. In many cases, the need for diagnostic surgical excision has been replaced by image-guided vacuum sampling.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Batohi B, Fang C, Michell MJ, et al. An audit of mammographic screen detected lesions of uncertain malignant potential (B3) diagnosed on initial image guided needle biopsy: how has our practice changed over 10 years? Clin Radiol. 2019. PMID: 31078275. doi:10.1016/j.crad.2019.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。